Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Expertise in Travel Health
    • Our ESG Commitments
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • COVID-19 Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access Policy
    • Scientific Publications
  • Investors
    Investors Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Financial & Filings
      • Financial Reports
      • SEC Filings
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • General Meetings
      • 2023 Combined General Meeting
      • 2022 Combined General Meeting
      • June 23, 2022 Special Meeting
      • General Meeting Archive
    • Videos and Webcasts
    • FAQ
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contacts
  • Careers
Contact
  • EN
  • FR
  • | DE
Search

Press Releases

October 21, 2009

Vivalis confirms its sound financial position 2009 nine-month revenue: €3.8 million Net cash stable in third quarter at €24.7 million

October 13, 2009

Vivalis accelerates marketing of the EB66® cell line in North America

September 29, 2009

GlaxoSmithKline signs an agreement with Kaketsuken to codevelop cell-culture based influenza vaccines in Japan based on Vivalis EB66® cell line

September 14, 2009

Participant at the Midcap Event in Paris on September 21st and 22nd 2009

September 8, 2009

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer

August 31, 2009

2009 first half: substantial improvement in performance Operating income: €4.9 million (+86%) Confirmation of 2009 targets: Net cash at year-end 2009 > €20 million Signature of 10 license agreements

August 25, 2009

Finalists from Germany, France and Switzerland nominated for the EUROPEAN BIOTECHNICA AWARD 2009

July 22, 2009

ROBUST FIRST-HALF GROWTH: NET CASH SURPLUS OF €1.8 MILLION IN THE FIRST HALF SOLID CASH POSITION AT 06/30/09 OF €24.5 MILLION +€3 MILLION RECEIVED FROM OSEO ISI IN EARLY JULY

July 15, 2009

VIVALIS AND INTERVET/SCHERING-PLOUGH ANIMAL HEALTH SIGN A COMMERCIAL LICENSE TO USE THE EB66® CELL LINE FOR VIRAL VACCINE PRODUCTION AND EVALUATE THE PLATFORM FOR 12 NEW VACCINES.

June 30, 2009

NEW RESEARCH LICENSE AGREEMENT FOR ANTIBODIES 2009 COMMERCIAL TARGETS RAISED: 10 NEW LICENSE AGREEMENTS

  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 51

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2023 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT REJECT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website. Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website. For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you. The information collected through these tracking and performance cookies do not identify any individual visitor.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT